LI-RADS CT/MRI v2018 Liver Observation — Structured Report

LI-RADS v2018 deterministic report for at-risk patients. Records major features and assigned LR category; pipes category into the decision engine.

CT / MRILiverv2LI-RADS CT/MRI v2018 →

Report inputs

LI-RADS v2018 deterministic report for at-risk patients. Records major features and assigned LR category; pipes category into the decision engine.

Exam & risk factors

Exam type

Cirrhosis

Chronic HBV

Prior HCC

Observations

Segment

Location

Size(mm)

Growth

Threshold growth

Non-rim APHE

Non-peripheral washout

Enhancing capsule

Restricted diffusion

Mild-moderate T2 hyperintensity

Fat in mass

Iron sparing

HBP hypointensity

Mosaic architecture

Nodule-in-nodule

Targetoid morphology

Infiltrative appearance

Tumor in vein

Major features: 0

LI-RADS: LR-3

Extrahepatic & other

Extrahepatic nodes

Peritoneal disease

Osseous metastases

Pulmonary metastases

Adrenal metastases

Portal vein thrombosis

Other findings

Summary

Overall LI-RADSLR-3

Overall LI-RADS: LR-3.

Staging / Classification

Overall LI-RADSLR-3
Observations1

Impression

• Overall LI-RADS category: LR-3 across 1 observation(s). Intermediate probability of HCC. Repeat multiphase MRI/CT in 3–6 months per AASLD/LI-RADS.

Full report

EXAM & RISK FACTORS
- Exam type: MRI-EOB
- Cirrhosis: —
- Chronic HBV: —
- Prior HCC: —

OBSERVATIONS
- Observations:
  1. Tumor in vein: none

EXTRAHEPATIC & OTHER
- Extrahepatic nodes: —
- Peritoneal disease: —
- Osseous metastases: —
- Pulmonary metastases: —
- Adrenal metastases: —
- Portal vein thrombosis: —
- Other findings: —

IMPRESSION
• Overall LI-RADS category: LR-3 across 1 observation(s). Intermediate probability of HCC. Repeat multiphase MRI/CT in 3–6 months per AASLD/LI-RADS.

Overall LI-RADS: LR-3

MANAGEMENT
• Repeat multiphase MRI/CT in 3–6 months per AASLD/LI-RADS.

FOLLOW-UP
• Repeat multiphase MRI/CT in 3–6 months per AASLD/LI-RADS.

Based on LI-RADS CT/MRI v2018.

Management / Follow-up

Management

• Repeat multiphase MRI/CT in 3–6 months per AASLD/LI-RADS.

Follow-up

• Repeat multiphase MRI/CT in 3–6 months per AASLD/LI-RADS.

Evidence

ACR CT/MRI LI-RADS v2018 assigns LR-1 through LR-5 based on non-rim APHE and major features (non-peripheral washout, enhancing capsule, threshold growth), stratified by observation size. — ACR LI-RADS v2018/2024.
Targetoid morphology or infiltrative appearance categorizes an observation as LR-M (probably or definitely malignant, not HCC-specific).
Unequivocal tumor in vein (enhancing soft tissue within a vein) categorizes as LR-TIV, a definite macrovascular malignancy.